Public-Private Collaborations Drive Advancements In Anemia And Blood Disorder Drug Development Trend: A Crucial Influence on the Anemia And Other Blood Disorder Drugs Market's Transformation in 2025

What Is the Expected Size and Growth Rate of the Anemia And Other Blood Disorder Drugs Market?
The market size for drugs related to anemia and other blood disorders has seen robust growth in the past years. The market is projected to increase from $11.61 billion in 2024 to $12.38 billion in 2025, progressing at a compound annual growth rate (CAGR) of 6.6%. The amplified growth during the previous periods can be credited to factors such as disease prevalence, international health initiatives, the aging population, innovation in pharmaceutical, and raised patient awareness.

Over the upcoming years, a substantial increase is expected in the market for drugs treating anemia and other blood disorders. It is projected that this market will expand to a value of $16.09 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.8%. Various elements such as emerging markets, global demographics and economic factors are credited for this growth in the forecasted period. Some other significant trends contributing to this market expansion include advancements in research and development, technology, biologics and targeted therapies. The growth is also reinforced by gene therapies, telemedicine and remote monitoring, granting of orphan drug designations, along with mergers and acquisitions.

What Factors Are Fueling Growth in the Anemia And Other Blood Disorder Drugs Market?
The growing occurrence of anemia across the globe greatly influences the market. Unhealthy living styles, evolving eating habits, and heightened stress levels have escalated anemia cases globally. For example, the highest incidence of anemia was detected amidst the elderly group (> 65 years old), with a prevalence rate nearing 17%. The World Bank declared anemia to be the 8th primary cause of disease among women and youth. The escalation in the rate of prevalence for anemia fuels the anemia and other blood disorder medication market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

Which Leading Companies Are Shaping the Growth of the Anemia And Other Blood Disorder Drugs Market?
Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc

What Are the Major Trends Shaping the Anemia And Other Blood Disorder Drugs Market?
Firms operating in the anemia and other blood disorder medications sector are partnering with governmental bodies to co-develop and commercialize a specific type of drug, a process that involves sharing knowledge, technology, and expenses. Such partnerships also offer benefits to these companies in situations where licenses are nearing expiration and regulatory conditions are strict. To illustrate, Disc Medicine declared in March 2023 that it would be joining forces with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) to carry out Phase 1/2 and Phase 2 clinical tests of biopterin for Diamond-Blackfan Anemia (DBA) patients and to treat adult patients who suffer from iron deficiency anemia. These studies, to be funded and conducted by the NIH, are part of a cooperative research and development agreement (CRADA).

What Are the Key Segments of the Anemia And Other Blood Disorder Drugs Market?
The anemia and other blood disorder drugs market covered in this report is segmented -

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Region Dominates the Anemia And Other Blood Disorder Drugs Market?
North America was the largest region in the anemia and other blood disorder drugs market in 2023. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Is Covered In The Anemia And Other Blood Disorder Drugs Global Market Report?

- Market Size Analysis: Analyze the Anemia And Other Blood Disorder Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Anemia And Other Blood Disorder Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Anemia And Other Blood Disorder Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Anemia And Other Blood Disorder Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2465

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.